WHO Calls for Expressions of Interest in Developing Sabin-IPV

Safe and affordable inactivated polio vaccine for low-income countries.

One of the strategic priorities of the Global Polio Eradication Initiative is to enable low-income countries to produce Inactivated Polio Vaccine (IPV). To meet this objective,  the World Health Organization is working with academia, government and industry to develop an IPV  based on the non-infectious Sabin virus strain (sIPV). A range of manufacturers and research institutes have active programmes at various stages of development. The development and licensure of IPV produced from Sabin strains aims to reduce the number of manufacturing sites generating high volumes of high titre wild polioviruses for ”traditional” IPV production. Sabin polioviruses pose less of a threat in the event of an intentional or unintentional release from the production facility. This is a particular concern in low-income countries where the transmissibility of polioviruses is high.


Related News

Carolyn Sein, Technical Officer for the GPEI programme, talks to us about circulating vaccine-derived polioviruses, and the important differences between oral polio vaccine, and inactivated polio vaccine.
In Afghanistan, blood tests are identifying where vaccination campaigns are working, and where gaps remain to be filled.
GPEI is seeking research proposals to accelerate polio eradication
Researchers have taken one step closer to poliovirus-free vaccine production
Research is delivering faster, cheaper and easier ways to administer the injectable inactivated polio vaccine to every last child
With SAGE recommending the use of fractional doses of the inactivated polio vaccine, a solution has been found to address global supply constraints